Influx Health. (INFLUX)

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Exceptional ROCE of 60.16%, indicating highly efficient use of capital
• Strong growth momentum: sales up 38.91% and profits up 78.11%
• Low PEG ratio of 0.46, suggesting attractive growth relative to valuation
• High promoter holding of 73.53%, aligning management with minority shareholders
• Solid Piotroski F-Score of 7/9, reflecting healthy financial fundamentals

Concerns

• Earnings lumpiness: latest quarter profit of ₹10 Cr vs. trailing annual profit of ~₹17.67 Cr raises sustainability questions
• P/E of 27.17 offers little margin of safety if growth decelerates
• Missing data (book value, ROE, debt/equity) prevents full balance sheet assessment
• Zero dividend yield means total return depends entirely on future capital gains

AI Analysis

When I look at Influx Health, I see a business that demands attention but also caution. A 60.16% ROCE is extraordinary—it tells me management is deploying capital with remarkable efficiency, a hallmark of a business with some genuine economic moat, even if I cannot yet name its source. Sales are growing at 38.91% and profits at 78.11%, which is the kind of compounding that makes value investors sit up. The PEG ratio of 0.46 suggests that, despite a P/E of 27.17, the market may be underpricing the growth. Promoter holding of 73.53% aligns interests, and a Piotroski F-Score of 7/9 indicates solid financial health. But I must be skeptical. The latest quarter shows sales of ₹67 Cr and net profit of ₹10 Cr—yet trailing earnings imply only ~₹17.67 Cr annually. That single quarter contributes over half the year's profit, so either this is a seasonal spike or something non-repeatable. Without book value, ROE, or debt figures, I cannot fully assess the balance sheet risk. The dividend yield is zero, so returns must come purely from reinvestment and capital appreciation. At ₹275.65, with a 52-week range of ₹196.50 to ₹315.00, the stock is not at a distressed price. I would want to see if this growth is sustainable, whether the quarterly surge becomes the norm, and why the market is offering a PEG this low. If the moat holds and capital discipline continues, Influx could be a wonderful business. But for now, I watch, I learn, and I wait for more data.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer